Cargando…

Impact of the Coronavirus Disease 2019 Pandemic on Global Lung Cancer Clinical Trials: Why It Matters to People With Lung Cancer

Detalles Bibliográficos
Autores principales:	Basu Roy, Upal, Baird, Anne-Marie, Ciupek, Andrew, Fox, Jesme, Manley, Eugene, Norris, XX, Kim, Scagliotti, Giorgio V., Wakelee, Heather A., Mitsudomi, Tetsuya, Clark, Russell C., Arndt, Renee, Hirsch, Fred R., Bunn, Paul A., Smeltzer, Matthew P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8695593/ https://www.ncbi.nlm.nih.gov/pubmed/34961851 http://dx.doi.org/10.1016/j.jtocrr.2021.100269

Ejemplares similares

International Association for the Study of Lung Cancer Study of the Impact of Coronavirus Disease 2019 on International Lung Cancer Clinical Trials
por: Smeltzer, Matthew P., et al.
Publicado: (2022)

PL02.09 International Association for the Study of Lung Cancer (IASLC) Study of the Impacts of COVID-19 on International Lung Cancer Clinical Trials
por: Smeltzer, M., et al.
Publicado: (2021)

A qualitative study of interactions with oncologists among patients with advanced lung cancer
por: Al Achkar, Morhaf, et al.
Publicado: (2022)

Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC status
por: Suda, Kenichi, et al.
Publicado: (2017)

Development of personalized treatments in lung cancer: focusing on the EGFR mutations and beyond
por: Suda, Kenichi, et al.
Publicado: (2013)

Patient Report on the Impact of Coronavirus Disease 2019 and Living With Lung Cancer
por: Chihuri, Tendai M., et al.
Publicado: (2023)

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations
por: Suda, Kenichi, et al.
Publicado: (2021)

Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy
por: Kobayashi, Yoshihisa, et al.
Publicado: (2016)

Salvage surgery after definitive chemoradiotherapy for patients with non-small cell lung cancer
por: Hamada, Akira, et al.
Publicado: (2021)

Cell Line Models for Acquired Resistance to First-Line Osimertinib in Lung Cancers—Applications and Limitations
por: Ohara, Shuta, et al.
Publicado: (2021)

Perioperative Therapy for Non-Small Cell Lung Cancer with Immune Checkpoint Inhibitors
por: Soh, Junichi, et al.
Publicado: (2021)

Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future Challenges
por: Fujino, Toshio, et al.
Publicado: (2021)

Contact with lung cancer patients during COVID-19: findings from Ireland and the UK from a global survey of patient experience
por: McNamara, Aoife, et al.
Publicado: (2022)

Utility of the Ba/F3 cell system for exploring on‐target mechanisms of resistance to targeted therapies for lung cancer
por: Koga, Takamasa, et al.
Publicado: (2022)

Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines
por: Suda, Kenichi, et al.
Publicado: (2017)

Adjuvant therapies in stages I–III epidermal growth factor receptor-mutated lung cancer: current and future perspectives
por: Kris, Mark G., et al.
Publicado: (2023)

The continued impact of the COVID-19 pandemic on patient advocacy and support organisations in the UK and Ireland: results from the second Global Lung Cancer Coalition (GLCC) survey
por: McNamara, Aoife, et al.
Publicado: (2022)

Importance of doctor‐initiated management of the balance between work and treatment for lung cancer patients: Results of a nationwide survey by the Japan Lung Cancer Society
por: Ikeda, Satoshi, et al.
Publicado: (2020)

Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?
por: Uramoto, H, et al.
Publicado: (2007)

Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer
por: Suda, Kenichi, et al.
Publicado: (2015)

Review of erlotinib in the treatment of advanced non-small cell lung cancer
por: Ganjoo, Kristen N, et al.
Publicado: (2007)

Advances in the Use of Targeted Therapies in the Management of Non–Small Cell Lung Cancer
por: Wakelee, Heather, et al.
Publicado: (2018)

Adjuvant Chemotherapy for Early Stage Non-Small Cell Lung Cancer
por: Patel, Manali I., et al.
Publicado: (2011)

Testing for COVID-19 in lung cancer patients
por: Passaro, A., et al.
Publicado: (2020)

Targeting Angiogenesis with Multitargeted Tyrosine Kinase Inhibitors in the Treatment of Non-Small Cell Lung Cancer
por: Scagliotti, Giorgio, et al.
Publicado: (2010)

Prognosis and segment-specific nodal spread of primary lung cancer in the right lower lobe
por: Tomizawa, Kenji, et al.
Publicado: (2015)

COVID-19 and Lung Cancer: A Comprehensive Overview from Outbreak to Recovery
por: Bungaro, Maristella, et al.
Publicado: (2022)

Clinical outcome of node‐negative oligometastatic non–small cell lung cancer
por: Sakai, Kiyohiro, et al.
Publicado: (2016)

The Survival Impact of Second Primary Lung Cancer in Patients With Lung Cancer
por: Choi, Eunji, et al.
Publicado: (2021)

Advances in lung cancer
por: Pacheco, Jose M., et al.
Publicado: (2017)

Changes in survival of patients with non–small cell lung cancer in Japan: An interrupted time series study
por: Taniyama, Yukari, et al.
Publicado: (2022)

Relationship of driver oncogenes to long term pemetrexed response in non-small cell lung cancer
por: Liang, Ying, et al.
Publicado: (2014)

Radiotherapy and Immunotherapy in Lung Cancer
por: Hsieh, Kristin, et al.
Publicado: (2023)

MRI of the lung (2/3). Why … when … how?
por: Biederer, J., et al.
Publicado: (2012)

Clinical and comparative utility of afatinib in non-small cell lung cancer
por: D’Arcangelo, Manolo, et al.
Publicado: (2014)

Collateral Chemoresistance to Anti-Microtubule Agents in a Lung Cancer Cell Line with Acquired Resistance to Erlotinib
por: Mizuuchi, Hiroshi, et al.
Publicado: (2015)

Smoking Cessation After Lung Cancer Diagnosis and the Risk of Second Primary Lung Cancer: The Multiethnic Cohort Study
por: Luo, Sophia J, et al.
Publicado: (2021)

Performance of Oncomine Fusion Transcript kit for formalin‐fixed, paraffin‐embedded lung cancer specimens
por: Sakai, Kazuko, et al.
Publicado: (2019)

Generation and characterization of MEK and ERK inhibitors- resistant non-small-cells-lung-cancer (NSCLC) cells
por: Iezzi, Alice, et al.
Publicado: (2018)

Activity and mechanism of acquired resistance to tarloxotinib in HER2 mutant lung cancer: an in vitro study
por: Koga, Takamasa, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_300jk4jt92fa4nn3sb4govsu3s